This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

McKesson (MCK) Gets a Buy from Barclays

Tipranks - Tipranks - Sat May 9, 5:00AM CDT

Barclays analyst Glen Santangelo maintained a Buy rating on McKesson today and set a price target of $1,050.00.

Claim 55% Off TipRanks

Santangelo covers the Healthcare sector, focusing on stocks such as Henry Schein, Cencora, and Medline. According to TipRanks, Santangelo has an average return of 3.6% and a 50.00% success rate on recommended stocks.

In a report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $1,012.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on McKesson’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $106.16 billion and a net profit of $1.19 billion. In comparison, last year the company earned a revenue of $95.29 billion and had a net profit of $879 million

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MCK in relation to earlier this year. Most recently, in February 2026, Maria Martinez, a Director at MCK sold 349.00 shares for a total of $328,011.14.

Read More on MCK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).